ChinaPeptides: difference between revisions
Diff·revision 45 → 46·14:05, 2 Jul 2025
Difference between revision 45 and revision 46 of ChinaPeptides. 5 lines changed; the page grew by 810 bytes.
| Revision 45 — 12:28, 25 Jun 2025 DefinedTermDov (talk) replace primary source with the review 8,278 bytes ±0 | Revision 46 — 14:05, 2 Jul 2025 SecondarySrc_Seb (talk) restructure 9,088 bytes +810 | ||
|---|---|---|---|
| 61 | The PeptidePedia tally records 902 self-reported submissions to July 2026. Recurring positive themes are custom-synthesis execution and mass-confirmation documentation; recurring complaints concern lead times and the two-name confusion.{{r|tally}} Self-selected; reception rather than quality.{{r|tally}} | 61 | The PeptidePedia tally records 902 self-reported submissions to July 2026. Recurring positive themes are custom-synthesis execution and mass-confirmation documentation; recurring complaints concern lead times and the two-name confusion.{{r|tally}} Self-selected; reception rather than quality.{{r|tally}} |
| 62 | 62 | ||
| + | 63 | == Regulatory position and legal status == | |
| + | 64 | The organisation is a commercial entity registered in the People's Republic of China. Nothing in the available record indicates a manufacturing authorisation, marketing authorisation or pharmacopoeial registration in any jurisdiction, and none should be inferred from a registered business scope, which is a licensing fact and not a quality assurance.{{r|registry}} | |
| + | 65 | ||
| + | 66 | Material labelled [[Research use only|for research use only]] is outside the regulatory framework that governs medicines. Its identity, purity, sterility and [[Bacterial endotoxin test|endotoxin]] content are not assured by any regulator, and a [[Certificate of analysis|certificate of analysis]] issued by a supplier is a claim by that supplier rather than an independent finding.{{r|ruo,usp1503}} | |
| + | 67 | ||
| 63 | == References == | 68 | == References == |
| 64 | {{reflist}} | 69 | {{reflist}} |